Most current approaches rely on adding nuclear localization signal (NLS) motifs to the ends of Cas9 to facilitate nuclear entry. However, this method is inefficient, and much of the Cas9 that is ...

A company’s plan to edit the genomes of human embryos worries some researchers — but it might reflect the changing attitudes towards the controversial approach.

The goal of gene therapy is to permanently cure hereditary diseases. One of the most promising technologies for this is the ...

Please provide your email address to receive an email when new articles are posted on . A CRISPR-Cas9-based therapy reduced transthyretin levels in patients with hereditary amyloidosis and ...

Both CRSP and NTLA are advancing in vivo gene editing therapies targeting large markets, with financial stability supporting ...

In the latest close session, CRISPR Therapeutics AG (CRSP) was down 6.54% at $68.29. The stock trailed the S&P 500, which registered a daily gain of 1.56%. On the other hand, the Dow registered a gain ...

CRISPR Therapeutics AG CRSP shares soared 8.7% in the last trading session to close at $76.78. The move was backed by solid volume with far more shares changing hands than in a normal session. This ...

In a separate 2024 study, researchers also made mice temporarily transparent. The study, published in Science, showed that ...

Lozano is a rare disease mom, neuroscience Ph.D. candidate at UC Davis, and board member for the PURA Syndrome Foundation. In May, a historic moment in science and medicine was captured in a single ...

‘Animation companies are under pressure, being asked to do more with less each year.’ Enter Unreal Engine, Epic Games’ Rob Di Figlia argued at MipJunior In unveils, Di Figlia sneak-peeked a 90-second ...

Is it the invasion of the genome snatchers? Just in case the idea of aliens walking around in human skin suits wasn’t frightening enough. An outlandish study asserts that aliens might have abducted us ...